A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in...

Clinical workflows to analyze variants of unknown significance (VUSs) found in clinical next generation sequencing (NGS) are labor intensive, requiring manual analysis of published data for each variant. There is a strong need for tools and resources that provide a consistent way to analyze variants. With the explosion of clinical NGS data and the concurrent availability of protein structures through the Protein Data Bank and protein models through programs such as AlphaFold, there exists an unprecedented opportunity to use structural information to help standardize NGS analysis with the overall goal of advancing personalized cancer therapy.

Using the Catalogue of Somatic Mutations in Cancer (COSMIC), the largest curated database of clinical cancer mutations, we mapped thousands of missense mutations in the kinase and juxtamembrane (JM) domains of 48 receptor tyrosine kinases (RTKs) onto structurally aligned kinase structures, then clustered known activating mutations along with VUSs based on proximity in three-dimensional structure. Using cell-based models we demonstrate that our resource can be used to aid in identification of activating mutations while providing insight into mechanisms of kinase activation and regulation.

We provide a database of structurally aligned and functionally annotated mutations that can be used as a tool to evaluate kinase VUSs based on their structural alignment with known activating mutations. The tool can be accessed through a user-friendly website in which one can input a kinase mutation of interest, and the system will output a list of structurally analogous mutations in other kinases, as well as their functional annotations.

Though our tool is not expected to be used as an isolated source for variant functional prediction, we expect our database will be a valuable addition to the current tools and resources used to analyze clinical NGS, with important clinical implications to guide recommendations for personalized cancer therapy.